This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    01/01/18

    Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia

    Ibrutinib is the first in-class, orally administered, Bruton's tyrosine kinase (BTK) inhibitor that abrogates the critical signaling downstream of the B-cell receptor (BCR).

    • Source: Therapeutic Advances in Hematology
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/05/16

    FDA approves label update for Imbruvica (ibrutinib) in chronic lymphocytic leukemia/small lymphocytic lymphoma- Janssen

    The FDA has approved an expansion to the U.S. Prescribing Information (PI) for Imbruvica (ibrutinib), from Janssen, based on data...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/03/16

    FDA approves Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL)- AbbVie + Janssen Biotech

    AbbVie announced that the FDA has approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL)....

    Blue test tubes arranged in a line, disappearing into the background
    News
    08/11/24

    Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia.- AstraZeneca

    Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukaemia (CLL) compared to ibrutinib .

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    30/10/18

    NICE does not recommend Venclyxto for use with Chronic Lymphocytic Leukaemia.- AbbVie + Roche.

    The National Institution for Health and Care Excellence (NICE) has in its second draft guidance rejected Venclyxto (venetoclax) from AbbVie/Roche...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    16/06/24

    Findings from landmark RESONATE-2 study confirm sustained survival benefit of Imbruvica (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up. Janssen-Cilag (J&J)

    J Janssen-Cilag International NV, a Johnson & Johnson company announced findings from the final analysis of the Phase III RESONATE-2 study, demonstrating a significant and sustained progression-free and overall survival benefit in patients with previously untreated chronic lymphocytic leukaemia (CLL) receiving Imbruvica (ibrutinib) monotherapy versus chlorambucil, at up to 10 years of follow-up.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    Interim analysis of the phase III ALPINE trial comparing Brukinsa to ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma to be reported at EHA 2021 virtual congress.-BeiGene

    BeiGene, Ltd. announced that results from the interim analysis of the Phase III ALPINE trial comparing Brukinsa (zanubrutinib) to ibrutinib (Imbruvica) in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will be reported in an oral presentation as part of the Presidential Symposium at the 26th European Hematology Association 2021 (EHA2021) Virtual Congress.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/06/22

    NICE (UK)recommends venetoclax for treatment of chronic lymphocytic leukemia.

    The National Institute for Health and Care Excellence (NICE)(UK); Venetoclax monotherapy is recommended, within its marketing authorisation, for treating chronic lymphocytic leukaemia (CLL) in adults

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    17/02/17

    NICE rejects Venclexta (venetoclax) as a treatment for chronic lymphocytic leukemia.- AbbVie + Roche

    The National Institution for Health and Care Excellence (NICE) has in its first draft guidance rejected Venclexta (venetoclax) from AbbVie...

    Journals
    Journal
    02/04/19

    Chronic lymphocytic leukaemia: the role of T cells in a B cell disease

    Chronic lymphocytic leukaemia (CLL) has long been thought to be an immunosuppressive disease and abnormalities in T-cell subset distribution and function have been observed in many studies. However, the role of T cells (if any)...

    • Source: British Journal of Haematology
    See more